Сингапур - Енглески - HSA (Health Sciences Authority)

taiho pharma asia pacific pte. ltd. - tipiracil hydrochloride 7.065mg eqv tipiracil; trifluridine - tablet, film coated - tipiracil hydrochloride 7.065mg eqv tipiracil 6.14mg; trifluridine 15mg

Сингапур - Енглески - HSA (Health Sciences Authority)

taiho pharma asia pacific pte. ltd. - tipiracil hydrochloride 9.420mg eqv tipiracil; trifluridine - tablet, film coated - tipiracil hydrochloride 9.420mg eqv tipiracil 8.19mg; trifluridine 20mg

Сингапур - Енглески - HSA (Health Sciences Authority)

qiagen singapore pte. ltd. - pathology - the therascreen kras rgq pcr kit is a real-time qualitative pcr assay used on the rotor-gene q mdx 5plex hrm or rotor-gene q 5plex hrm instrument for the detection of seven somatic mutations in the human kras oncogene using dna extracted from formalin fixed paraffin-embedded (ffpe) colorectal cancer (crc) tissue. the therascreen kras rgq pcr kit is intended to aid the clinician in identifying colorectal cancer patients who may not benefit from anti-epidermal growth factor receptor (egfr) therapy, such as panitumumab or cetuximab.

Сингапур - Енглески - HSA (Health Sciences Authority)

qiagen singapore pte. ltd. - pathology - the therascreen ras extension pyro kit is an in vitro diagnostic test based on pyrosequencing® technology for the quantitative detection of mutations in codons 59, 61, 117, and 146 of the human kras oncogene and codons 12, 13, 59, 61, 117, and 146 of the human nras oncogene, using dna extracted from formalin-fixed paraffin-embedded (ffpe) metastatic colorectal cancer (mcrc) human tissue. the therascreen ras extension pyro kit is intended to aid in the identification of mcrc patients more likely to benefit from anti-egfr therapies such as cetuximab and panitumumab. the therascreen ras extension pyro kit is for use only on the pyromark q24 system.

Израел - Енглески - Ministry of Health

medison pharma ltd - tipiracil as hydrochloride; trifluridine - film coated tablets - tipiracil as hydrochloride 6.14 mg; trifluridine 15 mg - trifluridine, combinations - colorectal cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.gastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Израел - Енглески - Ministry of Health

medison pharma ltd - tipiracil as hydrochloride; trifluridine - film coated tablets - tipiracil as hydrochloride 6.14 mg; trifluridine 15 mg - trifluridine, combinations - colorectal cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.gastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Израел - Енглески - Ministry of Health

medison pharma ltd - tipiracil as hydrochloride; trifluridine - film coated tablets - tipiracil as hydrochloride 8.19 mg; trifluridine 20 mg - trifluridine, combinations - colorectal cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.gastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Израел - Енглески - Ministry of Health

medison pharma ltd - tipiracil as hydrochloride; trifluridine - film coated tablets - tipiracil as hydrochloride 8.19 mg; trifluridine 20 mg - trifluridine, combinations - colorectal cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.gastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Израел - Енглески - Ministry of Health

amgen europe b.v. - bevacizumab - concentrate for solution for infusion - bevacizumab 25 mg / 1 ml - bevacizumab - mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.mvasi in addition to platinum - based chemotherapy is indicated for first - line treatment of adult patients with unresectable advanced metastatic or recurrent non- small cell lung cancer other than predominantly squamous cell histology.mvasi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. mvasi as a single agent, is indicated for the treatment of glioblastoma in patients with progressive disease following prior therapy.mvasi in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of advanced (figo stages iiib, iiic and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients who are at high risk for recurrence (residual disease after debulking).mvasi in combination with carboplatin and gemcitabine, is indicated for the treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents.mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin isindicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents.mvasi in combination with paclitaxel and cisplatin or paclitaxel and topotecan is indicated, in patients who cannot receive platinum therapy, for treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.mvasi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations.

Европска Унија - Енглески - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastic agents - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. for further information as to human epidermal growth factor receptor 2 (her2) status, please refer to section 5.1 of the smpc.aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. for further information as to her2 status, please refer to section 5.1 of the smpc.aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5.1 of the smpc).aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1 of the smpc).aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents.aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5.1 of the smpc).aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1 of the smpc).